Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

This study has been completed.
Xanodyne Pharmaceuticals
Information provided by:
Ferring Pharmaceuticals Identifier:
First received: January 19, 2011
Last updated: June 28, 2011
Last verified: June 2011
This was a multicenter, open-label extension study for subjects completing either of 2 pivotal efficacy studies (NCT00401193 or NCT00386308). The study consisted of a treatment phase of 9 menstrual periods to assess the safety of tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation. After the last treatment period, a follow-up phone call occurred approximately 30 days (range 25 to 35 days) after the last dose of study drug.

Condition Intervention Phase
Drug: Tranexamic acid
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-center, Open Label Extension Study to Evaluate the Safety of an Oral Dose of Tranexamic Acid (XP12B) Administered Three Times Daily During Menstruation for the Treatment of Menorrhagia

Resource links provided by NLM:

Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Participants With Treatment-Emergent Adverse Events (AEs) [ Time Frame: Day 1 to up to Month 9 ]
    Count of participants with treatment-emergent adverse events grouped in categories regarding relationship to study drug as assessed by the investigator, serious or life-threatening as assessed by the investigator, participants who died or their event led to withdrawal from study, and participants who experienced thrombotic or thromboembolic AEs.

Secondary Outcome Measures:
  • Participants With Abnormal Gynecological Examinations [ Time Frame: Day 1 to up to Month 9 ]
    Participants with abnormal gynecological examination findings based on endometrial biopsies and transvaginal ultraonogrphy (TVU) are summarized. Clinically significant results from the endometrial biopsies are results that are not benign. Abnormalities found during transvaginal ultrasonography (TVU) are detailed in the AE listings. Please refer to AE listings.

  • Mean Blood Pressure Measurements at Week 36 [ Time Frame: approximately week 36 ]
    Mean systolic and diastolic blood pressure measurements taken at week 36

  • Participants With Treatment Emergent Adverse Experiences (TEAE) of Laboratory Values Related to Treatment [ Time Frame: Day 1 to up to Month 9 ]
    Participants whose laboratory examinations (hematology, blood chemistry and urinalysis) were considered by the investigator to be treatment emergent adverse experiences (TEAE) and related to treatment. Also indicated is whether the TEAE lab parameter caused the participant to discontinue from the study.

  • Mean Intraocular Pressure at Month 9 [ Time Frame: Day 1 up to Month 9 ]
    Mean intraocular pressure at month 9 or the early termination visit.

  • Mean Fridericia-corrected QT Interval (QTcFRI) at Month 9 [ Time Frame: Month 9 ]
    The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization

Enrollment: 288
Study Start Date: April 2007
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tranexamic acid
Two 650 mg tablets orally 3 times per day with liquids for up to 5 days (not to exceed 3 doses in 1 day or 15 doses during the menstrual period).
Drug: Tranexamic acid
Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
Other Names:
  • XP12B
  • Lysteda


Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The study enrolled subjects who had completed the double-blind therapy in either the XP12B-MR-301 or XP12B-MR-303 study, including scheduled evaluations, with no major protocol violations and no study events that, in the opinion of the investigator, would preclude the subject's entry into the open-label safety study.
  • A negative urine pregnancy test was required immediately before entry into this study.
  • Women must have been surgically sterile or, if of childbearing potential, must have been in a monogamous relationship with a sterile partner or a partner of the same sex.
  • Women must have used an acceptable barrier contraception method with spermicide for the duration of the study or must have been using a copper intrauterine device (IUD).
  • In the opinion of the investigator, the subject must be able to understand this study, cooperate with all study procedures, be able to return to the study site for visits within the required visit windows and be deemed likely to complete the study.
  • Subject will provide voluntary, written consent to participate in the study by signing and dating an institutional review board (IRB)-approved informed consent before any procedures are performed or study drug is dispensed.

Exclusion Criteria:

  • History or presence of clinically significant hepatic or renal disease or other medical disease that might confound the study or be detrimental to the subject (e.g., clinically significant cardiac arrhythmia, uncontrolled diabetes or uncontrolled hypertension) as determined by the investigator.
  • Normal gynecological examination and breast examination.
  • Clinically significant abnormalities on screening physical examination that might confound the study or be detrimental to the subject as assessed by the investigator. Abnormal clinically significant electrocardiograms (ECG) as determined by the centralized cardiologist, or laboratory tests suggestive of a potential pituitary-prolactin stimulating tumor (prolactin >=30 µg/L), thrombocytopenia (platelet count <100,000/mm3), uncontrolled hypothyroidism (TSH >=10 mU/L) or severe anemia (hemoglobin <8 g/dL]).
  • Anovulatory dysfunctional uterine bleeding, metrorrhagia (irregular or frequent noncyclic flow), menometrorrhagia (irregular or frequent excessive noncyclic flow) or polymenorrhea (frequent flow, cycles of less than 21 days).
  • History or presence of endometrial polyps, endometrial hyperplasia, endometrial carcinoma or cervical carcinoma (includes cervical carcinoma in situ).
  • History of bilateral oophorectomy or hysterectomy.
  • Women who are pregnant, breastfeeding, planning to become pregnant during the study or become pregnant during the study.
  • History or active presence of myocardial infarction or ischemic disease. History or active presence of cerebrovascular accident, stroke, or transient ischemic attack.
  • History or presence of thrombosis, thromboembolic disease or coagulopathy including, but not limited to, pulmonary embolism, deep venous thrombosis, phlebitis and any intravascular clotting disorder.
  • History or known presence of acquired or inherited thrombophilia, including, but not limited to, antithrombin deficiency, Protein C and/or S deficiency, antiphospholipid deficiency, Factor V Leiden mutation and prothrombin mutation. Thalassemia or sickle cell disease (sickle cell trait individuals are not excluded).
  • History or presence of subarachnoid hemorrhage.
  • Use or anticipated use of medications taken to relieve β-Hydroxy β-methylbutyric acid (HMB) including the use of vaginal [rings, creams, gels] and transdermal hormone products; use of oral estrogen-, progestin- or SERM-containing drug products, or intrauterine progestins containing drug products. Use or anticipated use of Lupron (1 or 3 month) depot injection or estrogen pellet or long-acting progestin injectables.
  • Use or anticipated use of meclofenamate sodium, mefenamic acid, danazol, or desmopressin acetate or herbal remedies. Herbal remedies include, but are not limited to, Capsella bursa pastoris (i.e. Sheperd's Purse), Agnus castus (i.e. Chasteberry, Vitex), Cimicifuga racemosa (i.e. Black Cohosh), Symphytum officionale (i.e. Comfrey), and/or Angelica sinensis (i.e. Dong Quai).
  • Use of or anticipated use of the following drugs: oral, transdermal, injectable and vaginal ring (NuvaRing®) hormonal contraceptives; anticoagulants (warfarin [Coumadin®], heparin, low-molecular-weight heparin (LMWH), etc.), aminocaproic acid (Amicar®) or Plaquenil®.
  • Current use of an intrauterine device (IUD) other than copper IUDs.
  • History or presence of hypersensitivity or idiosyncratic reaction to antifibrinolytics (tranexamic acid or aminocaproic acid).
  • Use of any investigational drug except XP12B-MR during the current study.
  • Presence of untreated malabsorption disorder or malnutrition including, but not limited to, chronic diarrhea, celiac disease, short bowl syndrome, Whipple's disease or history of gastric bypass procedure.
  • Presence of defective color vision as determined by the optometrist or ophthalmologist. Inability of the subject to correctly identify symbols on plate 7 of the HRR eye test is not considered defective color vision provided the subject correctly identifies the symbols on plates 11-20.
  • History or presence of glaucoma, ocular hypertension, macular degeneration or retinopathies.
  • History or presence of alcoholism or drug abuse within the past year.
  • Malignancy, or treatment for malignancy, within the previous 2 years, with the exception of basal cell carcinomas of the skin or squamous cell carcinoma of the skin.
  • Does not read or understand English.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01280981

  Hide Study Locations
United States, Alabama
Radiant Research
Birmingham, Alabama, United States
United States, Arizona
Women's Health Research
Phoenix, Arizona, United States
Genova Clinical Research
Tucson, Arizona, United States
Quality of Life Medical and Research Center
Tucson, Arizona, United States
Radiant Research
Tucson, Arizona, United States
Visions Clinical Research
Tucson, Arizona, United States
United States, Arkansas
Lynn Institute of the Ozarks
Little Rock, Arkansas, United States
Searcy Medical Center
Searcy, Arkansas, United States
United States, California
Northern California Research Corp
Carmichael, California, United States
Physicians' Research Options, LC
Lakewood, California, United States
Sklar Center for Women's Wellness
Los Alamitos, California, United States
Medical Center for Clinical Research
San Diego, California, United States
INC Clinical Trials
Upland, California, United States
United States, Colorado
Advanced Women's Health Institute
Denver, Colorado, United States
Downtown Women's Health Care
Denver, Colorado, United States
United States, Florida
Nature Coast Clinical Research
Crystal River, Florida, United States
University of Florida
Gainesville, Florida, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
New Age Medical Research Corp
Miami, Florida, United States
University of Miami Cedars Medical Center
Miami, Florida, United States
Advanced Research Institute
New Port Richey, Florida, United States
Segal Institute for Clinical Research
North Miami, Florida, United States
United States, Georgia
Medical Network for Education & Research, Inc.
Decatur, Georgia, United States
United States, Idaho
The Women's Clinic
Boise, Idaho, United States
Rosemark Womencare Specialists
Idaho Falls, Idaho, United States
United States, Indiana
Provident Clinical Research
Bloomington, Indiana, United States
United States, Kansas
Wichita Clinic, P.A.
Newton, Kansas, United States
Radiant Research
Overland Park, Kansas, United States
United States, Louisiana
York Clinical Consulting
Marrero, Louisiana, United States
United States, Maryland
The Gynecology Center
Baltimore, Maryland, United States
United States, Michigan
ClinSite, LLC
Ann Arbor, Michigan, United States
Quest Research Institute
Bingham Farms, Michigan, United States
Grand Valley Gynecologists PC
Grand Rapids, Michigan, United States
Women's Health Care Specialist
Paw Paw, Michigan, United States
KMED Research
St. Clair Shores, Michigan, United States
United States, Missouri
Center for Pharmaceutical Research
Kansas City, Missouri, United States
United States, Montana
Montana Medical Research, Inc
Missoula, Montana, United States
United States, Nebraska
The Women's Center of Western Nebraska
Scottsbluff, Nebraska, United States
United States, Nevada
Office of R Garn Mabey, MD
Las Vegas, Nevada, United States
United States, New Jersey
Women's Health Research Center, LLC
Lawrenceville, New Jersey, United States
Phoenix OB-GYN Assoc, LLC
Moorestown, New Jersey, United States
United States, New York
American Clinical Trials
New York, New York, United States
United States, North Carolina
Duke Fertility Center
Durham, North Carolina, United States
Women's Wellness Center
Durham, North Carolina, United States
Lyndhurst Gynecologic Associates
Winston-Salem, North Carolina, United States
Piedmont Medical Research Associates
Winston-Salem, North Carolina, United States
United States, North Dakota
Mid Dakota Clinic
Bismarck, North Dakota, United States
United States, Ohio
Triphase Research Ltd
Centerville, Ohio, United States
Rapid Medical Research, Inc
Cleveland, Ohio, United States
University Suburban Health Center
Cleveland, Ohio, United States
Holzer Clinic
Gallipolis, Ohio, United States
Physicians Research, Inc.
Zanesville, Ohio, United States
United States, Oklahoma
LION Research
Norman, Oklahoma, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
United States, Oregon
Clinical Trials of America
Eugene, Oregon, United States
PMG/OB-GYN Health Center
Medford, Oregon, United States
The Portland Clinic
Portland, Oregon, United States
United States, Pennsylvania
Abington Reproductive Medicine, PC
Abington, Pennsylvania, United States
The Clinical Trial Center
Jenkintown, Pennsylvania, United States
Family Medical Associates Research Dept
Levittown, Pennsylvania, United States
Philadelphia Clinical Research, LLC
Philadelphia, Pennsylvania, United States
University of Pennsylvania, Dept. OB/GYN
Philadelphia, Pennsylvania, United States
Valley Forge OB/GYN
Phoenixville, Pennsylvania, United States
Research Across America
Reading, Pennsylvania, United States
Main Line OB/GYN
Strafford, Pennsylvania, United States
Wexford Professional Bldg II
Wexford, Pennsylvania, United States
United States, South Carolina
SC Clinical Research Center
Columbia, South Carolina, United States
Greenville Hospital System-Univ Med Group Dept
Greenville, South Carolina, United States
Greenville Pharmaceutical Research
Greenville, South Carolina, United States
Radiant Research
Greer, South Carolina, United States
United States, Tennessee
Bristol, Tennessee, United States
Southeastern Clinical Research
Chattanooga, Tennessee, United States
Alpha Clinical Research, LLC
Clarksville, Tennessee, United States
Volunteer Research Group
Knoxville, Tennessee, United States
Research Memphis Associates
Memphis, Tennessee, United States
Tennessee Women's Care, PC
Nashville, Tennessee, United States
United States, Texas
J&S Studies, Inc
College Station, Texas, United States
OB/GYN Infertility & Preventive Medicine
Dallas, Texas, United States
Phyllis Gee, MD
Plano, Texas, United States
King's Daughters Clinic
Temple, Texas, United States
Center of Reproductive Medicine
Webster, Texas, United States
Women's Healthcare
Woodlands, Texas, United States
United States, Utah
Mt. Timpanogos Women's Health Center
Pleasant Grove, Utah, United States
Jean Brown Research
Salt Lake City, Utah, United States
Physician's Research Options
Sandy, Utah, United States
Granger Medical OB/GYN
West Valley City, Utah, United States
United States, Vermont
FAHC, Womens Health Research
Burlington, Vermont, United States
United States, Virginia
Clinical Trials of Virginia, INC
Richmond, Virginia, United States
Tidewater Clinical Research, Inc.
Virginia Beach, Virginia, United States
United States, Washington
Valley Women's Clinic
Renton, Washington, United States
North Spokane Women's Center
Spokane, Washington, United States
United States, Wisconsin
Medical Associates Health Centers
Menomonee Falls, Wisconsin, United States
Sponsors and Collaborators
Ferring Pharmaceuticals
Xanodyne Pharmaceuticals
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Clinical Development Support, Ferring Pharmaceuticals Identifier: NCT01280981     History of Changes
Other Study ID Numbers: XP12B-MR-304
Study First Received: January 19, 2011
Results First Received: May 3, 2011
Last Updated: June 28, 2011

Keywords provided by Ferring Pharmaceuticals:
Heavy Menstrual Bleeding

Additional relevant MeSH terms:
Uterine Hemorrhage
Uterine Diseases
Genital Diseases, Female
Menstruation Disturbances
Pathologic Processes
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Coagulants processed this record on April 21, 2017